AP1M2

Across TCGA pan-cancer cohorts, AP1M2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AP1M2 data layer compared with 16 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher AP1M2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AP1M2 expression acts as an unfavorable survival marker.

BRCA, KICH, and OV are the cancer types where AP1M2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.001	0.907	<.001	14	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
OV	DFS	Median	II,III,IV	0.239	0.542	.045	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
MESO	OS	Median	II,III,IV	0.180	0.560	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AP1M2–BRCA (OS)

Open the BRCA breakdown →